Trial ID or NCT#
NCT00904163
Status
Purpose
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional characteristics of patients who survive to adulthood.
Official Title
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
M. Peter Marinkovich, MD
Dermatologist,
Blistering disease specialist,
Psoriasis specialist
Associate Professor of Dermatology
Paul A. Khavari, MD, PhD
Dermatologist,
Cutaneous oncology specialist,
Medical oncologist
Carl J. Herzog Professor of Dermatology in the School of Medicine
Contact us to find out if this trial is right for you.
CONTACT
Emily Gorell, MS
(650) 721-7166
View on ClinicalTrials.gov